Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Accurate Staging and Determining Resectability in NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video